Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer

Status unconfirmed · Phase 2

Conditions studied: Breast Neoplasms

In brief

The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.

Key facts

Study ID

NCT00415285

Run by

Georgia Center for Oncology Research & Education

People needed

100

Starts

2006-12-01

Last updated by the study team

2007-02-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed breast carcinoma.
• Early stage breast cancer (stage 1, 2, 3).
• No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.
• 18 years of age or older.
• Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

You may not qualify if…

• Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.
• Major surgery within 28 days of study entry.
• Evidence of CNS metastases.
• Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Where it is running

• Grady Memorial Hospital — Atlanta, Georgia, United States (enrolling)
• Emory Crawford Long Hospital — Atlanta, Georgia, United States (enrolling)
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.